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A B S T R A C T
The circadian disruption seen in patients of Huntington's disease (HD) is recapitulated in the R6/2 mouse
model. As the disease progresses, the activity of R6/2 mice increases dramatically during the rest (light) period
and decreases during the active (dark) period, eventually leading to a complete disintegration of rest-activity
rhythms by the age of ~16 weeks. The suprachiasmatic nucleus controls circadian rhythms by entraining the
rest-activity rhythms to the environmental light-dark cycle. Since R6/2 mice can shift their rest-activity rhythms
in response to a jet-lag paradigm and also respond positively to bright light therapy (1000 lx), we investigated
whether or not a prolonged day length exposure could reduce their daytime activity and improve their
behavioural circadian rhythms. We found that a long-day photoperiod (16 h light/8 h dark cycle; 100 lx)
signiﬁcantly improved the survival of R6/2 female mice by 2.4 weeks, compared to mice kept under standard
conditions (12 h light/12 h dark cycle). Furthermore, a long-day photoperiod improved the nocturnality of R6/2
female mice. Mice kept under long-day photoperiod also maintained acrophase in activity rhythms (a parameter
of rhythmicity strength) in phase with that of WT mice, even if they were symptomatic. By contrast, a short-day
photoperiod (8 h light/16 h dark cycle) was deleterious to R6/2 female mice and further reduced the survival by
~1 week. Together, our results support the idea that light therapy may be beneﬁcial for improving circadian
dysfunction in HD patients.
1. Introduction
Huntington's disease (HD) is a genetic neurodegenerative disorder
characterised by motor, cognitive and psychiatric symptoms. It is now
well-established that sleep disruption and circadian abnormalities are
symptoms associated with HD (for references, see Morton (2013)).
Disrupted rest-activity patterns observed in HD patients are recapitu-
lated in multiple HD mice models (Morton et al., 2005; Kudo et al.,
2011; Loh et al., 2013; Fisher et al., 2013, 2016). The R6/2 line of HD
mice with 250 CAG repeats exhibits a rapid progression in neurological
pathology that starts at ~6 weeks of age, and causes an early death at
~22 weeks of age (Wood et al., 2013). The circadian abnormalities
appear from the age of 10–12 weeks and result in a complete
disintegration of daily cycles by the age of 15–16 weeks (Wood et al.,
2013).
The circadian dysrhythmia in R6/2 mice is accompanied at the
molecular level by a temporal dysregulation of the clock genes in the
suprachiasmatic nucleus (SCN) and clock-dependent genes in periph-
eral tissues (Morton et al., 2005; Maywood et al., 2010). However, the
molecular machinery in the SCN of arrhythmic 16 week old R6/2 mice
remains intact; when the SCN from arrhythmic R6/2 mice were studied
ex vivo, they expressed normal electrophysiological output and normal
endogenous rhythms of circadian gene expression (Pallier et al., 2007).
This suggested that rather than being ‘broken’, the SCN is functionally
dysregulated in vivo by pathological aﬀerent input. Given that the
molecular machinery is intact, the SCN should be able to respond when
stimulated appropriately. In support of this idea, it has been shown
that pharmacological (Pallier et al., 2007) as well as non-pharmacolo-
gical interventions (e.g. temporally scheduled feeding (Maywood et al.,
2010) and bright light therapy associated with exercise (Cuesta et al.,
2014)) are able to improve the rest-activity rhythms of symptomatic
R6/2 mice.
In mammals, circadian rhythms are regulated via direct input from
retinal photoreceptors to the SCN. Retinal degeneration and functional
impairment have been reported in the R6 lines (Helmlinger et al.,
2002; Petrasch-Parwez et al., 2004; Batcha et al., 2012; Ragauskas
et al., 2014; Ouk et al., 2016), leading possibly to visual and non-visual
dysfunctions such as circadian photoreception. However, we have
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shown that R6/2 mice are able to respond to photic manipulations such
as 6 h jet-lag paradigm as well as 23 h-day (with light exposure at 100
lx) (Wood et al., 2013). We have also seen that the photoreceptors
responded to bright light therapy at 1000 lx (Cuesta et al., 2014).
Therefore, in the present study we manipulated the light/dark (LD)
cycles by changing the photoperiod length as a way to modify the rest-
activity rhythms of R6/2 mice.
Under the standard 12 h light/12 h dark cycle, R6/2 mice show a
breakdown in their rest-activity rhythms from around 15–16 weeks
(Wood et al., 2013), accompanied with a progressive general health
deterioration and loss of body weight. In this study, we hypothesised
that a prolonged daily light exposure would reduce aberrant daytime
activity. We tested the eﬀect of a long-day photoperiod (16 h light/8 h
dark cycle) on the rest-activity rhythms, body weight and survival of
R6/2 mice. For comparison, we also tested R6/2 mice under a short-
day photoperiod (8 h light/16 h dark cycle) and a standard photoperiod
(12 h light/12 h dark cycle).
2. Material and methods
2.1. Ethic statement
All experiments were carried out in accordance with the UK
Animals (Scientiﬁc Procedures) Act 1986, and with the approval of
the University of Cambridge Animal Welfare and Ethical Review Board.
2.2. Animals and housing conditions
Wild type (WT) and R6/2 mice were taken from a colony
established in the University of Cambridge (CBA x C57BL/6J back-
ground) and obtained following the breeding strategy used by Prof. Gill
Bates group (Mangiarini et al., 1996). The genotype and the number of
CAG repeats of each mouse were determined from tail snips by Laragen
(Los Angeles, USA) using GeneMapper (Morton et al., 2009) before,
and veriﬁed after, the experiments. The 72 R6/2 mice used in the whole
study had a mean CAG repeat length of 250 ± 1.
Prior to the experiments, mice were kept in their home cage, with a
maximum of 10 animals of the same sex and genotype in each cage.
The mice were maintained in a controlled environment with 12:12
light-dark cycle, room temperature of 21–23 °C and humidity of 55%
± 10, and had ad libitum access to dry laboratory food and water. All
mice were transferred to clean cages once weekly.
During the circadian studies, mice were housed individually in a
light-tight and sound-proof Scantainer ventilated cabinet (Scanbur,
Denmark) with controlled humidity (55% ± 10) and temperature (21–
23 °C), and a built-in light system (100 lx). Mice had ad libitum access
to food and water, which was delivered by lowered bottles with
elongated spouts to facilitate access for symptomatic R6/2 mice. The
activity of the mice was checked daily and the mice were visually
examined twice a week. As an indication of general well-being, mice
were weighed once a week throughout the study and then twice weekly
once the body weight of R6/2 mice started to decrease.
2.3. Analysis
Activity of the mice in circadian cages was recorded continuously
throughout the experiment with motion sensors (Bosch, Germany)
placed on top of each cage and connected to a computerised recording
system (Clocklab; Actimetrics, Evanston, IL, USA). Total activity data
were double plotted in actograms using 5-min bins. All behavioral
analyses were performed using Clocklab software. Period length was
calculated using a least-square ﬁts regression line using 7 continuous
activity onsets. The Chi-squared periodogram function of Clocklab was
used to verify strength of rhythmicity using a line of signiﬁcance at
0.001. Duration of the active period (alpha) was calculated as the
diﬀerence between the means of the regression lines drawn through the
activity onsets and corresponding oﬀsets. The distribution of the
general activity during the active and rest periods was determined
using the proﬁle activity function of the software. Rest-activity ratios
were calculated as the amount of activity occurring during the light
period as a fraction of the amount of activity occurring during the
nocturnal activity. Phase angle of activity to light onset and oﬀset was
calculated to determine the entrainment of the circadian locomotor
activity rhythms to the light-dark schedule. For this, we determined
mean time of day when mice were starting (or ending) their activity
phase using least-square regression lines ﬁtted to the activity onsets (or
oﬀsets) of the targeted time span. We then calculated the time
diﬀerence with local time when lights were on (or oﬀ). Time of activity
onsets and oﬀsets were also veriﬁed from the analysis of the proﬁle
activity. Only rhythmic mice were included in the analysis. Acrophase
(peak time) in activity rhythms, a parameter of rhythmicity strength,
was estimated using Clocklab function by ﬁtting the activity of each day
to a sine function with a period of 24 h. For each parameter, data were
averaged across 7 consecutive days. General activity during active and
rest period was determined using the proﬁle activity function of the
software.
2.4. Lighting conditions
All the mice were ﬁrst placed in the circadian cabinet at 8 weeks of
Fig. 1. Experimental time and light schedule for photoperiod testing. Circadian data were collected from mice placed under four diﬀerent photoperiod lengths: standard condition
(12:12 LD cycle), long-day photoperiod (16:8 LD cycle), short-day photoperiod (8:16 LD cycle) and DD (constant darkness). Lights oﬀ was set at the same local time of 19:00 for
standard, long- and short-day photoperiods.
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age under 12:12 LD cycle (lights on at 7 am and oﬀ at 7 pm) for 1 week
of habituation. After this, the photoperiod was either maintained or
changed (Fig. 1), with the light oﬀset remaining at 7 pm.
Three lighting conditions were used. In the ﬁrst condition (stan-
dard), WT and R6/2 mice (n = 8 for males and n = 9 for females) were
maintained under standard light-dark conditions (12:12 LD cycle) for
the remainder of the experiment.
In the second condition (long day), at 9 weeks of age, WT and R6/2
mice (n = 10 for males and n = 8 for females) were placed for one week
under 14:10 LD cycle (lights on at 5 am and oﬀ at 7 pm), and at 10
weeks of age shifted to a 16:8 LD cycle (lights on at 3 am and oﬀ at
7 pm) for the remainder of the experiment.
In the third condition (short day), at 9 weeks of age, WT and R6/2
mice (n= 8 for WT male, n= 10 for R6/2 male, n = 9 for both WT and
R6/2 female mice) were placed for one week under 10:14 LD cycle
(lights on at 9 am and oﬀ at 7 pm), and then at 10 weeks of age shifted
to a 8:16 LD cycle (lights on at 11 am and oﬀ at 7 pm) for the
remainder of the experiment.
Finally, we wanted to compare the eﬀect of light/dark cycles and the
eﬀect of constant darkness (DD) on the rest-activity rhythms of R6/2
mice throughout their lifespan. For this, we used and reanalysed a set
of data obtained from WT and R6/2 mice placed under DD from a
previous published experiment (Cuesta et al., 2012). In that study, WT
and R6/2 mice (n = 9 for each genotype and each sex) were placed in
the cabinet under DD between the ages of 8–20 weeks.
2.5. Survival
Mice were killed when they reached a deﬁned end point, that was
when they were considered moribund e.g. when they did not exhibit a
righting reﬂex, or failed to rouse in response to gentle stimulation.
2.6. Statistics
All data are expressed as mean ± SEM except for the survival
curves. Statistical analyses were performed using StatSoft Statistica
19.0 software (version 12, StatSoft Inc., Tulsa, USA) or Prism 5
(GraphPad Software Inc., San Diego, USA). Analysis of variance
(ANOVA) with repeated measures was performed to investigate
diﬀerences between groups, followed by Bonferroni post hoc test.
Survival data were analysed using the Mantel-Cox Log-rank test. The
results were considered signiﬁcant when P < 0.05.
3. Results
3.1. Long-day condition has a beneﬁcial eﬀect on rest-activity
rhythms of R6/2 female mice
WT mice were rhythmic throughout the study regardless of the
photoperiod condition (Figs. 2A, D, G; 3A, D, G). The rest-activity
rhythms of R6/2 mice became progressively disrupted, as expected
(Morton et al., 2005; Wood et al., 2013; Cuesta et al., 2014), regardless
of the photoperiod under which the mice were placed (Figs. 2B, E, H;
3B, E, H). Nevertheless, the analysis of periodograms showed that
exposure to long-day photoperiod delayed the disruption of rest-
activity rhythms of R6/2 female mice (Fig. 2C, F, I). Under standard
condition and short-day photoperiod, the periodograms showed that
amplitude of the rest-activity rhythms of R6/2 female mice decreased
dramatically at 14–16 weeks compared to 10–12 weeks (Fig. 2C, I).
This decrease in rhythm amplitude was smaller in R6/2 females of 14–
16 weeks under long-day photoperiod (Fig. 2F). As for R6/2 male mice,
they were already dysrhythmic at 14–16 weeks irrespective of the
photoperiod (Fig. 3B, C, E, F, H, I).
3.2. Long photoperiod has a beneﬁcial eﬀect on survival and body
weight of R6/2 female mice
The most striking eﬀect of the diﬀerent photoperiods tested was
seen in the survival data of R6/2 female mice (Fig. 4A). Long-day
photoperiod signiﬁcantly extended the lifespan of R6/2 female mice by
2.4 weeks compared to mice placed under standard condition (20.3 ±
0.6 weeks; P < 0.05), short-day photoperiod (19.3 ± 0.3 weeks; P <
0.05) and DD (20.1 ± 0.6 weeks; P < 0.05). By contrast, short-day
photoperiod signiﬁcantly reduced the lifespan in R6/2 female mice
compared to standard condition and DD (P < 0.05). There was no
signiﬁcant eﬀect of photoperiod length in R6/2 male mice (Fig. 4B).
WT mice grew steadily from 10 weeks of age until the end of the
experiment, irrespective of the photoperiod (Fig. 5A, B). By contrast,
R6/2 female mice exhibited a decline in body weight from the age of 15
weeks under both standard condition and short-day photoperiod
(Fig. 5C). However, weight loss of R6/2 female mice under long-day
photoperiod was signiﬁcantly delayed for ~3 weeks compared to short-
day photoperiod and standard condition (age x genotype eﬀect [F (8,88)
= 11.01; P < 0.001] and [F (9,63) = 4.70; P < 0.001] respectively). The
weight loss of R6/2 male mice started at the age of 13 weeks,
irrespective of the photoperiod, and continued until the end of the
experiment (Fig. 5D). There were small signiﬁcant diﬀerences when
body weight of R6/2 male mice under long-day photoperiod was
compared to short-day photoperiod or standard condition, but this is
unlikely to be clinically relevant.
3.3. Entrainment to LD cycles is normal in R6/2 mice until the HD-
phenotype is advanced
To determine if the beneﬁcial eﬀect of long-day photoperiod on
survival was accompanied by changes in rest-activity rhythms, we
analysed the circadian parameters of R6/2 mice placed under diﬀerent
photoperiods.
The endogenous period length of R6/2 female mice placed under
DD progressively decreased compared to WT mice, with the diﬀerence
being signiﬁcant from 12–20 weeks of age (P < 0.05, Table 1). When
placed under diﬀerent photoperiods, R6/2 female mice were able to
entrain to the new LD cycles, and there were no diﬀerences in their
period length (~24 h) compared to those of WT mice, until the rest-
activity rhythms of R6/2 mice disintegrated (week 17 for short-day
photoperiod and weeks 21–22 for long-day photoperiod).
The alpha of female WT and R6/2 mice varied directly according to
the time allocated to darkness (Table 2). There was a main eﬀect of
photoperiod length on alpha of both WT female [F (3,31) = 28.11; P <
0.001] and R6/2 female [F (3,19) = 21.01; P < 0.001] mice. Under DD,
the endogenous alpha was ~14 h for both WT and R6/2 mice. Under
standard condition and short-day photoperiod, mean alpha for WT
mice was of 12.2 ± 0.3 h and 12.7 ± 0.3 h respectively. Under long-
day photoperiod, mean WT alpha was of 10.3 ± 0.7 h, with the active
phase conﬁned mainly to the 8 hours of darkness. Under the diﬀerent
photoperiod lengths, R6/2 female mice responded the same way as WT
mice until the rest-activity rhythms disintegrated. Under long-day
photoperiod, we found a main eﬀect of age x genotype interaction on
alpha [F (12,120) = 13.61; P < 0.001], which was explained by the alpha
of R6/2 mice progressively increasing from 10.1 ± 0.4 h at 10 weeks of
age up to 14.9 ± 1.1 h at the age of 22 weeks.
To investigate the daily photic synchronisation in R6/2 mice, we
analysed the phase angles of entrainment to light onset and oﬀset
under each photoperiod condition (Fig. 6). Normal mice entrain to
standard light-dark cycle with active period starting when lights are oﬀ
and ending when the lights are on. Phase angles are parameters to
analyse the preciseness of the circadian entrainment. A phase angle is
positive when the activity starts before the light cue occurs and is
negative when it starts after. We found a signiﬁcant eﬀect of age x
genotype interaction on phase angles regardless of the photoperiod
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length tested. Under standard condition, both WT and R6/2 mice had
similar phase angles of entrainment to lights on (Fig. 6A) and lights oﬀ
(Fig. 6B) until the age of 15–17 weeks when phase angles of R6/2 mice
became signiﬁcantly more positive compared to WT mice (P < 0.05).
This diﬀerence increased with age until the phase angle of synchroni-
sation of the R6/2 mice could no longer be calculated as their rest-
activity rhythms had disintegrated.
Under long-day photoperiod, both WT and R6/2 female mice
entrained similarly to the light oﬀset until the age of 17 weeks
(Fig. 6D), as the phase angle of R6/2 mice was progressively more
positive compared to WT mice (+5 h vs. 1 h, P < 0.05). Concomitantly,
they both had a negative phase angle to light onset, with that of R6/2
female mice becoming signiﬁcantly diﬀerent from that of WT female
mice from the age the 18 weeks (Fig. 6C). As a result, R6/2 female mice
had their active period shifted in the light period.
Under short-day photoperiod, both WT and R6/2 female mice
entrained similarly to the light oﬀset (Fig. 6F) until the age of 16 weeks,
when the positive phase angle for R6/2 became signiﬁcantly larger
(R6/2 mice, +2.77 ± 1.08 h vs WT mice, -0.85 ± 0.06 h, P < 0.01).
Both WT and R6/2 mice anticipated the light onset set at 11 am by
around 3 hours between 10–17 weeks (Fig. 6E).
The diﬀerent photoperiod lengths had no signiﬁcant eﬀect on
period length in R6/2 male mice compared to WT mice
(Supplementary Table S1). The alpha of R6/2 male mice was similar
to that of WT mice under standard condition and short-day photo-
period. Signiﬁcant diﬀerences were only seen in R6/2 male mice under
long-day photoperiod who had a longer alpha from the age of 17 weeks
compared to WT mice (Supplementary Table S2). R6/2 male mice
entrained to the standard condition similarly to the WT mice, until the
age of 15–16 weeks when the phase angles became signiﬁcantly more
positive (Supplementary Fig. S1A, B). Under long-day and short-day
photoperiods, phase angles of entrainment to light onset was similar
between R6/2 and WT male mice (Supplementary Fig. S1C, E). The
diﬀerences were seen only for the phase angles to light oﬀset when the
R6/2 mice anticipated their active period signiﬁcantly earlier than WT
mice from 14 weeks (long-day photoperiod) and 16 weeks (short-day
photoperiod) (Supplementary Fig. S1D, F).
In summary, our data showed that R6/2 mice were at ﬁrst able to
entrain their rest-activity rhythms to the LD cycles in a manner similar
to that of WT mice, but they progressively anticipated the light oﬀset as
their phenotype advanced, by starting their active period signiﬁcantly
earlier than the WT mice.
3.4. Long photoperiod improves nocturnality and rest-activity
rhythms in R6/2 mice
We analysed the percentage of activity during the dark period in
order to determine the level of nocturnality of R6/2 female mice placed
under the diﬀerent photoperiod lengths (Fig. 7A, C, E). Under long-day
photoperiod, we found signiﬁcant age- and genotype-related changes in
Fig. 2. Disintegration of rest-activity rhythms in R6/2 female mice under diﬀerent photoperiods. Representative rest-activity proﬁles show general activity measured in WT (A, D, G)
and R6/2 female mice (B, E, H) under standard condition (A, B), long-day photoperiod (D, E) and short-day photoperiod (G, H). Periodograms are shown for R6/2 mice (C, F, I) for each
photoperiod, from 10 to 12 weeks (left), 14 to 16 weeks (middle) and 18 to 20 weeks (right). The lines in the periodograms indicate the level of signiﬁcance (P < 0.001). Note the
diﬀerent age axis for D and E compared to A, B, G and H.
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the percentage of activity during the dark period [age eﬀect, F (12,144) =
8.27; P < 0.001; genotype eﬀect, F (1,144) = 15.40; P < 0.01; Fig. 7C]
as well as an age x genotype interaction [F (12,144) = 4.34; P < 0.001].
Similar eﬀects were seen under standard condition and short-day
photoperiod (Fig. 7A, E). While in WT mice the percentage of activity
during the dark period was steady throughout the study for each
photoperiod (79.6 ± 0.1% under standard condition, 66.1 ± 0.1%
under long-day photoperiod and 86.9 ± 0.4% under short-day
photoperiod), the activity of R6/2 mice during the dark period
progressively decreased. Post hoc analyses revealed that the diﬀerences
in R6/2 mice compared to WT mice became signiﬁcant at 14 weeks of
age under short-day photoperiod (Fig. 7E; P < 0.05), 18 weeks under
standard condition (Fig. 7A; P < 0.05), and 20 weeks under long-day
photoperiod (Fig. 7C, P < 0.05). In order to compare nocturnal
behaviour, we looked at the 19 weeks age point: in WT mice, 81% of
their activity occurred during the dark period under standard condi-
tion, 91% under short-day photoperiod, and 67% under long-day
photoperiod. For R6/2 mice, 50% of their activity occurred during
Fig. 3. Disintegration of rest-activity rhythms in R6/2 male mice under diﬀerent photoperiods. Representative rest-activity proﬁles show general activity measured in WT (A, D, G) and
R6/2 male mice (B, E, H) under standard condition (A, B), long-day photoperiod (D, E) and short-day photoperiod (G, H). Periodograms are shown for R6/2 mice (C, F, I) for each
photoperiod, from 10 to 12 weeks (left), 14 to 16 weeks (middle) and 18 to 20 weeks (right). The lines in the periodograms indicate the level of signiﬁcance (P < 0.001). Note the
diﬀerent age axis for D and E compared to A, B, G and H.
Fig. 4. Beneﬁcial eﬀect of long-day photoperiod on survival of R6/2 female mice. Kaplan-Meier survival curves are shown for R6/2 female (A) and male (B) mice under standard
condition (white triangle symbols), long day (white circle symbols), short day (grey circle symbols) and DD (constant darkness, black circle symbols).
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the dark period (4.2% per hour of dark) under standard condition, 44%
under long-day photoperiod (5.5% per hour of dark) and 54% under
short-day photoperiod (3.4% per hour of dark). In R6/2 males, the
percentage of activity per hour of dark was similar to R6/2 female mice
with 5.5% under long-day photoperiod, 4.1% under standard condition
and 4.2% under short-day photoperiod (Supplementary Fig. S2A, C, E).
We analysed the activity ratio (light/dark) of R6/2 female mice
placed under the diﬀerent photoperiod lengths (Fig. 7B, D, F). We
found signiﬁcant age- and genotype-related changes in the activity ratio
[genotype eﬀect, F (1,140) = 16.47; P < 0.002 and age eﬀect, F (14,140) =
14.16; P < 0.001 respectively] as well as an age x genotype interaction
[F (14,140) = 12.16; P < 0.001]. Whilst the ratio remained constant over
time for the WT mice (0.15 under standard condition, 0.55 under long-
day photoperiod and 0.70 under short-day photoperiod), that of R6/2
female mice was at ﬁrst similar to that of WT mice and then increased
progressively; and the diﬀerence was signiﬁcant from the age of 19
weeks (short-day photoperiod, P < 0.01), 18 weeks (standard photo-
period, P < 0.01), and 17 weeks (long-day photoperiod, P < 0.01).
The light/dark activity ratio in R6/2 male mice under diﬀerent
photoperiod was similar to that of female mice (Supplementary Fig.
S2B, D, F).
Finally, we analysed the acrophase of general activity, as a para-
Fig. 5. Long-day photoperiod delays body weight loss in R6/2 female mice. Body weight of WT female (A), WT male (B), R6/2 female (C) and R6/2 male (D) mice are shown from 10 to
23 weeks under standard condition (grey symbols), short-day (black symbols) and long-day (white symbols) photoperiods. Dotted line in each panel shows body weight (100%) at the age
of 10 weeks. All data shown are mean ± SEM. Where error bars are not visible, they are obscured by the symbols. Where data are missing from groups, this was because mice were killed
at end stage. Asterisks indicate statistical diﬀerence between long-day photoperiod and standard condition and hashes between long-day and short-day photoperiods. No statistical
diﬀerence was found between standard condition and short-day photoperiod. *P < 0.05, #P < 0.05.
Table 1
Effect of different daily light exposure on period length of WT and R6/2 female mice.
DD Short day Standard condition Long day
Age WT R6/2 WT R6/2 WT R6/2 WT R6/2
10 weeks 23.72 ± 0.06 (9) 23.34 ± 0.04 (9) 24.00 ± 0.02 (9) 23.93 ± 0.06 (9) 23.99 ± 0.02 (9) 23.94 ± 0.03 (9) 24.07 ± 0.08 (8) 24.00 ± 0.03 (8)
11 weeks 24.03 ± 0.10 (9) 23.47 ± 0.07 (9) 24.01 ± 0.02 (9) 23.96 ± 0.06 (9) 23.98 ± 0.03 (9) 24.02 ± 0.03 (9) 23.97 ± 0.02 (8) 23.92 ± 0.06 (8)
12 weeks 23.94 ± 0.07 (9) 23.24 ± 0.06 (9)* 24.00 ± 0.02 (9) 23.99 ± 0.04 (9) 23.95 ± 0.04 (9) 23.93 ± 0.02 (9) 23.97 ± 0.02 (8) 23.94 ± 0.05 (8)
13 weeks 24.23 ± 0.09 (9) 23.33 ± 0.05 (9)** 24.00 ± 0.02 (9) 24.02 ± 0.05 (9) 24.00 ± 0.03 (9) 24.02 ± 0.06 (7) 24.00 ± 0.03 (8) 23.98 ± 0.05 (8)
14 weeks 23.86 ± 0.08 (9) 23.1 ± 0.09 (8) 24.00 ± 0.01 (9) 24.02 ± 0.06 (9) 24.00 ± 0.02 (9) 23.92 ± 0.04 (7) 23.97 ± 0.04 (8) 23.93 ± 0.05 (8)
15 weeks 23.92 ± 0.09 (9) 23.22 ± 0.08 (8)** 24.00 ± 0.01 (9) 23.87 ± 0.06 (9) 24.00 ± 0.02 (9) 23.92 ± 0.04 (7) 24.00 ± 0.03 (8) 23.88 ± 0.07 (8)
16 weeks 24.12 ± 0.04 (9) 23.26 ± 0.20 (8)* 24.07 ± 0.02 (9) 23.74 ± 0.1 (9) 24.00 ± 0.03 (9) 23.97 ± 0.06 (6) 24.03 ± 0.03 (8) 23.82 ± 0.07 (8)
17 weeks 24.10 ± 0.05 (9) 23.03 ± 0.12 (8)** 24.01 ± 0.01 (9) 23.81 ± 0.1 (9)** 23.98 ± 0.01 (9) 23.84 ± 0.07 (6) 23.99 ± 0.03 (8) 23.96 ± 0.05 (8)
18 weeks 24.07 ± 0.12 (9) 22.80 ± 0.16 (7)** 23.98 ± 0.03 (9) 24.00 ± 0.15 (6) 23.99 ± 0.03 (9) 23.91 ± 0.07 (5) 24.01 ± 0.04 (8) 23.8 ± 0.03 (7)
19 weeks 23.85 ± 0.05 (9) 22.72 ± 0.11 (2)** 24.04 ± 0.04 (9) 23.96 ± 0.02 (9) 23.99 ± 0.20 (2) 23.99 ± 0.02 (8) 23.83 ± 0.14 (7)
20 weeks 23.89 ± 0.04 (9) 23.21 ± 0.10 (2)* 24.02 ± 0.01 (9) 23.99 ± 0.02 (9) 23.83 (1) 23.99 ± 0.02 (8) 23.96 ± 0.20 (6)
21 weeks 24.01 ± 0.03 (9) 24.04 ± 0.02 (9) 24.08 ± 0.03 (8) 23.63 ± 0.15 (6)**
22 weeks 23.97 ± 0.02 (9) 23.92 ± 0.04 (9) 24.03 ± 0.02 (8) 23.49 ± 0.15 (4)**
23 weeks 24.02 ± 0.04 (8) 23.75 ± 0.57 (2)
*P < 0.05; **P < 0.01.
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meter of rhythmicity strength (Fig. 8). We found age- and genotype-
related changes as well as an age x genotype interaction for standard
condition (Fig. 8A) and short-day photoperiod (Fig. 8C). For both LD
cycles, the activity acrophase of R6/2 female mice progressively
occurred closer to the light oﬀset at 7 pm, with signiﬁcant diﬀerences
found at 18 weeks (short-day photoperiod, P < 0.05) and from 19
weeks (standard condition, P < 0.01) compared to WT mice (Fig. 8A,
C). Under long-day photoperiod, although we found a main eﬀect of
genotype on the acrophase of R6/2 female mice [F (1,10) = 7.34; P <
0.05], post hoc analyses did not reveal any signiﬁcant diﬀerences at any
age (Fig. 8B). The activity acrophase of the R6/2 female mice under
long-day photoperiod remained 2–3 hours after the light oﬀset, similar
to that of WT mice. The analysis of acrophase in R6/2 males showed an
important variability and therefore diﬀerences with WT mice were not
signiﬁcant until end stage at 20 weeks under long-day photoperiod (P
< 0.01) and 22 weeks under short-day photoperiod (Supplementary
Fig. S3; P < 0.05).
In summary, our data suggested that increasing the light period
from 12 to 16 h and shortening the dark period from 12 to 8 h forced
the R6/2 female mice to be more 'nocturnal', keeping their activity
acrophase in the dark period and increasing the percentage of activity
in darkness when compared to that of other photoperiods.
4. Discussion
We found that long-day photoperiod prolonged the lifespan of R6/2
female mice by 2.4 weeks, slowed body weight loss and had beneﬁcial
eﬀects on the rest-activity rhythms. Long days improved the nocturn-
ality of R6/2 female mice and maintained the acrophase in activity
rhythms in phase to that of WT mice, until late symptomatic ages.
These eﬀects were not seen in R6/2 male mice tested at the same age.
The prolonged lifespan in R6/2 female mice placed under long-day
condition is of particular interest. Although we have identiﬁed a
number of manipulations that improved neurological function, few of
the pharmacological or behavioural manipulations we tried resulted in
improved survival in R6/2 mice. For example, chronic treatment with
levodopa (L-DOPA) or methamphetamine (0.005% in the drinking
water) improved motor abnormalities and rest-activity rhythms in R6/
2 mice, but both reduced survival (Hickey et al., 2002; Cuesta et al.,
2012). Interestingly, treatment with modaﬁnil/alprazolam (Pallier
et al., 2007), or creatine (Ferrante et al., 2000) improved survival in
R6/2 mice irrespective of sex while preconditioning treatment with 3-
nitropropionic acid (Skillings and Morton, 2016) improved survival
only in female mice. It has been shown by others that both exposure to
an enriched environment from an early age, and voluntary physical
exercise delays the onset of neurological signs in R6/1 transgenic HD
mice (van Dellen et al., 2000, 2008; Pang et al., 2006). In the case of
R6/2 mice, we have shown that environmental enrichment improved
both neurological function and cognitive performance, and that this
behavioural paradigm can have deleterious (Skillings et al., 2014) or
beneﬁcial eﬀects (Carter et al., 2000; Wood et al., 2010, 2011) on
survival. To our knowledge, there is no other behavioural manipulation
shown to improve survival in R6/2 mice. For instance, temporally
scheduled feeding and bright light therapy associated with restricted
period of voluntary exercise had deleterious or no eﬀect on survival
although they improved behavioural abnormalities (Cuesta et al.,
2014). It is possible that the long-day photoperiod induces its beneﬁcial
eﬀects via an increase in both physical activity in the cage and sensory
stimulation. Both of these have a direct and beneﬁcial inﬂuence on the
morphology of the medium spiny neurons of the striatum (Comery
et al., 1996; van Dellen et al., 2000; Spires et al., 2004).
The fact that the eﬀect of long-day photoperiod was seen only on
R6/2 female mice is interesting. Studies in transgenic R6/1 HD mice
reveal a sexual dimorphism in neuroendocrine (serotoninergic and
dopaminergic systems), physiological and behavioural endopheno-
types, as well as depressive-like behaviours (Renoir et al., 2011,
2014; Du et al., 2015). Interestingly, a sex-dependent delay in onset
of circadian phenotype is observed in both R6/2 and BACHD mouse
models of HD (Kuljis et al., 2016). Since R6/2 male mice exhibit a
circadian disruption earlier than was observed in females, it is possible
that the beneﬁcial eﬀects of the long-day photoperiod might have been
observed in males if we had started testing them at an earlier age.
Indeed, the HD phenotype of male R6/2 mice may have been too
advanced at the time we started the experiment to see an eﬀect. The
reason that female HD mice develop their circadian phenotype later
than male mice is unclear. Several other studies suggest that there are
protective mechanisms in female HD mice or rats (Dorner et al., 2007;
Bode et al., 2008; Wood et al.; 2010). Indeed, there is growing evidence
that the role of estrogen is not conﬁned to regulation of ovulation and
reproductive behaviour in females of mammalian species (Gillies and
McArthur, 2010), but that estrogen also exerts an antioxidant action as
a free radical scavenger (Bellanti et al., 2013), with profound eﬀects on
learning, memory, mood and neurodegenerative process. Furthermore,
there is clinical and basic evidence of a neuroprotective role of estrogen
in neurodegenerative diseases such as Parkinson's disease and
Alzheimer's disease (McEwen and Alves, 1999; Garcia-Segura et al.,
2001; Greenﬁeld et al., 2002; Brann et al., 2007; Garcia-Segura, 2008).
In HD patients, there is little evidence of a sex diﬀerence in the age at
Table 2
Effect of different daily light exposure on duration of active period of WT and R6/2 female mice.
DD Short day Standard condition Long day
Age WT R6/2 WT R6/2 WT R6/2 WT R6/2
10 weeks 13.98 ± 0.35 (9) 14.43 ± 0.56 (9) 11.83 ± 0.22 (9) 12.67 ± 0.42 (9) 12.81 ± 0.25 (8) 13.10 ± 0.29 (9) 10.45 ± 0.75 (8) 10.13 ± 0.40 (8)
11 weeks 14.37 ± 0.33 (9) 14.68 ± 0.48 (9) 12.31 ± 0.26 (9) 12.92 ± 0.40 (9) 12.95 ± 0.28 (8) 13.04 ± 0.31 (9) 10.40 ± 0.60 (8) 10.15 ± 0.30 (8)
12 weeks 14.13 ± 0.21 (9) 14.86 ± 0.62 (9) 12.21 ± 0.24 (9) 13.38 ± 0.38 (9) 12.81 ± 0.30 (8) 12.62 ± 0.45 (9) 10.15 ± 0.53 (8) 10.04 ± 0.34 (8)
13 weeks 14.35 ± 0.25 (9) 14.86 ± 0.62 (9) 12.16 ± 0.23 (9) 13.32 ± 0.43 (9) 12.79 ± 0.33 (8) 12.86 ± 0.54 (7) 10.35 ± 0.56 (8) 10.53 ± 0.50 (8)
14 weeks 14.35 ± 0.35 (9) 15.50 ± 0.37 (9) 12.38 ± 0.25 (9) 13.26 ± 0.47 (9) 12.57 ± 0.30 (8) 12.90 ± 0.54 (7) 10.22 ± 0.53 (8) 10.22 ± 0.40 (8)
15 weeks 14.38 ± 0.25 (9) 16.34 ± 0.47 (9) 12.44 ± 0.18 (9) 13.12 ± 0.45 (9) 12.59 ± 0.20 (8) 13.00 ± 0.32 (7) 10.44 ± 0.60 (8) 11.26 ± 0.47 (8)
16 weeks 14.77 ± 0.19 (9) 15.79 ± 0.65 (7) 12.54 ± 0.30 (9) 14.04 ± 0.70 (9) 12.71 ± 0.21 (8) 12.43 ± 0.67 (6) 10.33 ± 0.70 (8) 11.89 ± 0.57 (8)
17 weeks 14.19 ± 0.38 (9) 14.16 ± 0.48 (7) 12.54 ± 0.32 (9) 14.09 ± 0.82 (8) 12.57 ± 0.29 (8) 12.74 ± 0.65 (6) 10.32 ± 0.54 (8) 12.70 ± 1.13 (8)
18 weeks 13.84 ± 0.34 (9) 15.20 ± 0.67 (7) 12.05 ± 0.23 (9) 13.18 ± 1.20 (6) 12.91 ± 0.34 (8) 13.31 ± 0.77 (5) 10.23 ± 0.67 (8) 12.02 ± 0.29 (7)
19 weeks 13.79 ± 0.28 (9) 16.01 ± 0.62 (5) 12.03 ± 0.0 (9) 12.76 ± 0.44 (8) 12.88 ± 0.22 (2) 10.14 ± 0.72 (8) 13.20 ± 0.40 (7)
20 weeks 14.57 ± 0.42 (9) 15.36 (1) 12.08 ± 0.28 (9) 12.77 ± 0.30 (8) 13.75 (1) 10.14 ± 0.75 (8) 13.24 ± 0.64 (6)
21 weeks 16.73 (1) 12.12 ± 0.25 (9) 12.63 ± 0.34 (8) 10.64 ± 0.74 (8) 13.96 ± 0.71 (6)
22 weeks 12.38 ± 0.38 (9) 12.92 ± 0.41 (8) 10.27 ± 0.67 (8) 14.95 ± 1.05 (4)*
23 weeks 10.15 ± 0.65 (8) 17.25 ± 1.26 (3)
*P < 0.05.
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onset or rate of disease progression. However, a study using a
transgenic rat model of HD demonstrated that decreased levels of
17β-estradiol (the most active of the estrogens) correlated with reduced
numbers of striatal DARPP32-positive medium-sized spiny neurons in
male mice. These neurons are those that are primarily aﬀected in the
neurodegenerative process of HD (Bode et al., 2008). This suggests a
neuroprotective eﬀect of estrogen in HD.
Under standard and long-day conditions, the negative masking
induced by light that suppresses locomotor activity (Mrosovsky, 1999),
exerted a pressure on both WT and R6/2 mice to compress their
activity (alpha) into the hours of darkness. The entrainment of rest-
activity rhythms to the LD cycles by R6/2 mice was progressively less
precise as the phenotype advanced, particularly under long-day
photoperiod. The anticipation of active phase compared to lights oﬀ
seen in R6/2 female mice under long-day photoperiod is likely to be
due to the shortening of the endogenous period seen under DD in
symptomatic R6/2 mice compared to WT mice. This progressive lack of
entrainment to lights oﬀ may be explained by a progressive deﬁcit in
negative masking and/or a progressive insensitivity to light preventing
the R6/2 mice from synchronizing more precisely to the LD cycles.
Photoreception occurs in the retina in mammals, via the intrinsically
photosensitive retinal ganglion cells that express the photopigment
melanopsin, and also via inputs from rods and cones. Retinopathies
have been described in R6 lines (Helmlinger et al., 2002; Ragauskas
et al., 2014), and we have found that melanopsin and cone opsin
expression is downregulated in R6/2 mice as well as in the full length
Fig. 6. Phase angles of entrainment are progressively abnormal in R6/2 female mice. Histograms show the phase angle of entrainment to light onset (A, C, E) or oﬀset (B, D, F) for WT
(open histograms) and R6/2 (ﬁlled histograms) mice placed under standard condition (A, B), long-day photoperiod (C, D) and short-day photoperiod, (E, F). Data were calculated
separately and averaged across 7 days and presented as mean ± SEM. *P < 0.05, **P < 0.01. The section sign (§) indicates age after which deaths or arrhythmicity of R6/2 mice made
analysis impossible. The number of mice kept under standard conditions was 9 WT and 9 R6/2 mice, under the long-day photoperiod was 8 WT and 8 R6/2 mice and under the short-
day photoperiod was 9 WT and 9 R6/2 mice. When numbers of R6/2 mice started to decrease, they are indicated in parentheses in the graphs.
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knock-in HD Q175 mice (Ouk et al., 2016), suggesting a progressive
deﬁcit in light detection at the level of the HD retina. Therefore, it is
possible that a disease-related change in photoreception by the retina
contributes to the progressive dysregulation of circadian rhythmicity
and entrainment seen in R6/2 mice. We found that increasing the daily
light exposure from presymptomatic stage in R6/2 female mice (when
the retina was still normal) reinforced the rest-activity rhythms under
long-day photoperiod.
The mechanisms underlying the beneﬁcial eﬀect of long day and
short night on survival in female R6/2 mice are not known. Since
changing the photoperiod length improved the rest-activity rhythms of
female R6/2 mice, we speculate that photoperiods may also aﬀect
functions such as sleep and metabolism that are circadian-dependent.
It has been shown that sleep-wake architecture of R6/2 mice under
standard-day condition becomes particularly aberrant during the dark
period (Kantor et al., 2013), with wake amount being dramatically
decreased as the symptomatic R6/2 mice progressively lose their ability
to maintain long bouts of wakefulness. Concomitantly, both non-rapid
eye movement (REM) sleep and REM sleep amounts are doubled in the
dark period compared to WT mice. No changes however, were found
during the 12 h of light. The SCN has been shown to play a prominent
role in the circadian regulation of sleep-wake states (Lee et al., 2009),
therefore the increase in REM sleep during the dark period may be
caused by a circadian dysregulation. The sleep disruption in R6/2 mice
is accompanied by the appearance of a pathological increase in gamma
activity (Fisher et al., 2013; Kantor et al., 2013). It would be interesting
to determine, in R6/2 mice, whether or not the beneﬁcial and
deleterious eﬀects on survival of long-day photoperiod and short-day
Fig. 7. Eﬀect of photoperiod length is diﬀerent on general activity parameters of female WT and R6/2 mice. Percentage of nocturnal activity (A, C, E) and light/dark activity ratio (B, D,
F) are shown for WT (open symbols) and R6/2 (ﬁlled symbols) mice placed under standard condition (A, B), long-day (C, D) and short-day (E, F) photoperiods. Data were averaged
across 7 days and presented as mean ± SEM. Where error bars are not visible, they are obscured by the symbols. *P < 0.05, **P < 0.01. The section sign (§) indicates age after which
deaths or arrhythmicity of R6/2 mice made analysis impossible. The number of mice kept under standard conditions was 9 WT and 9 R6/2 mice, under the long-day photoperiod was 8
WT and 8 R6/2 mice and under the short-day photoperiod was 9 WT and 9 R6/2 mice. When the numbers of R6/2 mice started to decrease, they are indicated in parentheses in the
graphs.
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photoperiod, respectively, are reﬂected in the sleep-wake architecture
and the spectral electroencephalography. We speculate that the con-
solidation of sleep would be improved with long-day photoperiod, as
this improved the nocturnality of R6/2 mice.
Disturbances in circadian pacemaking are not restricted to the
brain in R6/2 mice, but also encompass peripheral metabolic pathways
(Maywood et al., 2010). In parallel with the circadian disruption, R6/2
mice exhibit a weight loss associated with an increased metabolism,
revealed by an increase in oxygen consumption (van der Burg et al.,
2008). They also exhibit severe metabolic deﬁcits such as diabetes
(Menalled and Chesselet, 2002; Goodman et al., 2008). The improve-
ment in survival in R6/2 female mice placed under long-day photo-
period was accompanied by a delay in body weight loss compared to
short-day photoperiod and standard condition. Although body weight
does not correlate with survival in the R6/2 mice (Wood et al., 2010), it
is a good marker for disease onset and stage of phenotype. Recent
studies suggested that photoperiod lengths in normal mice had a
signiﬁcant eﬀect on metabolism (Pyter et al., 2007; Kooijman et al.,
2015). For instance, a 16:8 LD cycle prevented the metabolic con-
sequences of circadian disruption via activation of brown adipose tissue
(Kooijman et al., 2015), whereas a 8:16 LD cycle had deleterious eﬀects
on the hypothalamic-pituitary-adrenal (HPA) axis responsiveness with
increases in corticosterone responses to restraint (Pyter et al., 2007).
Since metabolism and HPA axis are progressively abnormal in R6/2
mice (Björkqvist et al., 2006; Maywood et al., 2010), it would be
interesting to study the eﬀects of long- and short-day photoperiods at a
molecular level in R6/2 mice, with particular reference to liver
metabolism. The improved survival under long-day photoperiod we
observed may be paralleled by delayed metabolic deﬁcits in R6/2 mice.
Circadian abnormalities have been associated with mood disorder
such as depression (Landgraf et al., 2016), which is a common
psychiatric symptom of HD (Slaughter et al., 2001; Paulsen et al.,
2005; Julien et al., 2007). R6/2 mice also develop depressive and
anxiety-like behaviours (Ciamei et al., 2015). Bright light therapies
have been shown to be beneﬁcial in the treatment of depression
(Golden et al., 2005; Pail et al., 2011) as well as circadian disruption
in Parkinson's (Willis and Turner, 2007) and Alzheimer's disease
(Dowling et al., 2007). Bright light was an eﬃcient intervention to
improve rest-activity rhythms of R6/2 mice (Cuesta et al., 2014). In our
current study, we found that increasing the period of light exposure at
100 lx from 12 to 16 h was as beneﬁcial to R6/2 female mice as
increasing the light intensity during 12 h at 1000 lx. This also supports
the idea that the behavioural circadian abnormalities are not only due
to photoreception deﬁcit but also to a circadian ‘brain’ deﬁcit.
In conclusion, we found that a prolonged day length exposure at
low light levels from a presymptomatic age had beneﬁcial eﬀects on
both survival and on the strength of the circadian rhythmicity in R6/2
female mice. Therefore, photoperiod length seems to be a powerful way
to regulate the rest-activity rhythms of R6/2 female mice, when
modulated at an appropriate stage of the disease. These ﬁndings
support the idea that if the length of daily exposure to light is regulated
in HD patients, this may help with the treatment of circadian
abnormalities.
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